• POS1425 ANTIB2GLYCOPROTEIN I ANTIBODIES CAN INDUCE NETOSIS 

  Mancuso, S; Giacomassi, C; Truglia, S; Barbati, C; Alessandri, C; Corsiero, E; Caliste, M; Lewis, M; Bombardieri, M; Conti, F (BMJ, 2023-06)

• Development and performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), consisting of frequently active clinical domains, in two randomised controlled trials in primary Sjogren's syndrome 

  de Wolff, L; Arends, S; Pontarini, P; Bombardieri, M; Bowman, SJ; Bootsma, H (2021)

• Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. 

  Retamozo, S; Acar-Denizli, N; Horváth, IF; Ng, W-F; Rasmussen, A; Dong, X; Li, X; Baldini, C; Olsson, P; Priori, R (2021)

  OBJECTIVES: To analyse how the main components of the disease phenotype (sicca symptoms, diagnostic tests, immunological markers and systemic disease) can be driven by the age at diagnosis of primary Sjögren's syndrome ...

• Severity of COVID-19 infection in primary Sjogren's syndrome and the emerging evidence of COVID-19-induced xerostomia 

  Chowdhury, F; Grigoriadou, S; Bombardieri, M (2021)

• COMPOSITE OF RELEVANT ENDPOINTS IN SJOGREN'S SYNDROME (CRESS): A COMPREHENSIVE TOOL FOR CLINICAL TRIALS 

  Arends, S; de Wolff, L; Van Nimwegen, JF; Verstappen, GM; Vehof, J; Bombardieri, M; Bowman, SJ; Pontarini, E; Baer, A; Nys, M (2021)

• Addressing the clinical unmet needs in primary Sjogren's Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts 

  Pezoulas, VC; Goules, A; Kalatzis, F; Chatzis, L; Kourou, KD; Venetsanopoulou, A; Exarchos, TP; Gandolfo, S; Votis, K; Zampeli, E (2022)

• RITUXIMAB PREVENTS WORSENING OF B-CELL DRIVEN SALIVARY GLAND INFLAMMATION AND EXCRETORY FUNCTION IN PRIMARY SJOGREN'S SYNDROME: RESULTS FROM THE TRACTISS TRIAL 

  Pontarini, E; Chowdhury, F; Sciacca, E; Grigoriadou, S; Emery, P; Ng, WF; Sutcliffe, N; Rivellese, F; Tappuni, A; Lucchesi, D (2022)

• High-throughput sequencing of IgH gene in minor salivary glands from Sjogren's syndrome patients reveals dynamic B cell recirculation between ectopic lymphoid structures 

  Carlotti, E; Murray-Brown, W; Blighe, K; Caliste, M; Astorri, E; Sutcliffe, N; Tappuni, AR; Pitzalis, C; Corsiero, E; Bombardieri, M (2022)

• Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. 

  Hernández-Molina, G; Kostov, B; Brito-Zerón, P; Vissink, A; Mandl, T; Hinrichs, AC; Quartuccio, L; Baldini, C; Seror, R; Szántó, A (2022-12-23)

  OBJECTIVE: To characterize 414 patients with primary SS who developed haematological malignancies and to analyse how the main SS- and lymphoma-related features can modify the presentation patterns and outcomes. METHODS: ...

• Immunofibroblasts regulate LTα3 expression in tertiary lymphoid structures in a pathway dependent on ICOS/ICOSL interaction 

  Nayar, S; Pontarini, E; Campos, J; Berardicurti, O; Smith, CG; Asam, S; Gardner, DH; Colafrancesco, S; Lucchesi, D; Coleby, R (2022)

• Examining the biological pathways underlying clinical heterogeneity in Sjogren's syndrome: proteomic and network analysis 

  Berry, JS; Tarn, J; Casement, J; Duret, P-M; Scott, L; Wood, K; Johnsen, S-J; Nordmark, G; Devauchelle-Pensec, V; Seror, R (2023)

• Composite of Relevant Endpoints for Sjogren's Syndrome (CRESS): development and validation of a novel outcome measure 

  Arends, S; de Wolff, L; van Nimwegen, JF; Verstappen, GMPJ; Vehof, J; Bombardieri, M; Bowman, SJ; Pontarini, E; Baer, AN; Nys, M (2021)

• DEVELOPMENT AND PRELIMINARY VALIDATION OF THE SJOGREN'S TOOL FOR ASSESSING RESPONSE (STAR): A CONSENSUAL COMPOSITE SCORE FOR ASSESSING TREATMENT EFFECT IN PRIMARY SJOGREN'S SYNDROME 

  Seror, R; Baron, G; Camus, M; Cornec, D; Perrodeau, E; Bowman, SJ; Bombardieri, M; Bootsma, H; Gottenberg, JE; Fisher, B (2022)

• The glucose transporter 2 regulates CD8+ T cell function via environment sensing. 

  Fu, H; Vuononvirta, J; Fanti, S; Bonacina, F; D'Amati, A; Wang, G; Poobalasingam, T; Fankhaenel, M; Lucchesi, D; Coleby, R (2023-11)

  T cell activation is associated with a profound and rapid metabolic response to meet increased energy demands for cell division, differentiation and development of effector function. Glucose uptake and engagement of the ...

• Performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), an Adjusted ESSDAI Score, in Two Randomised Clinical Trials in Patients with Primary Sjogren's Syndrome 

  de Wolff, L; Arends, S; Pontarini, E; Bombardieri, M; Bowman, SJ; Bootsma, H (2021)

• Highlights of the 15th International Symposium on Sjogren's Syndrome 

  Baldini, C; Bartoloni, E; Bombardieri, M (2022)

• Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjogren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study 

  Price, E; Bombardieri, M; Kivitz, A; Matzkies, F; Gurtovaya, O; Pechonkina, A; Jiang, W; Downie, B; Mathur, A; Mozaffarian, A (2022)

• Stepwise changes in the murine salivary gland immune response during virally-induced ectopic lymphoid structure formation 

  Coleby, R; Lucchesi, D; Pontarini, E; Pitzalis, C; Bombardieri, M (2021)

• PD-L1 signaling on human memory CD4+T cells induces a regulatory phenotype 

  Fanelli, G; Romano, M; Nova-Lamperti, E; Sunderland, MW; Nerviani, A; Scotta, C; Bombardieri, M; Quezada, SA; Sacks, SH; Noelle, RJ (2021)

• Is minor salivary gland biopsy still mandatory in Sjogren's syndrome? Does seronegative Sjogren's syndrome exist? 

  Baldini, C; Berardicurti, O; Giacomelli, R; Bombardieri, M (2023-08-25)

  Sjӧgren's disease (SjD) is a systemic autoimmune disorder characterized by the chronic inflammation and dysfunction of exocrine glands, mainly salivary glands, causing dryness of the eyes and of the mouth. The disease may ...

View more